Abstract
Calciphylaxis or calcific uremia arteriopathy (CUA) is a rare and highly morbid condition that predominantly affects dialyzed end-stage renal disease (ESRD) patients1. One-year survival rate is estimated to be 40-50%, with sepsis emerging as the leading cause of death 2. Calciphylaxis presents with painful necrotic cutaneous ulcers, livedo racemosa, hemorrhagic patches, indurated plaques, or hemorrhagic bullae predominantly on the proximal lower extremities and trunk 2.
This article is protected by copyright. All rights reserved.
http://ift.tt/2q9M77i
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου